TP53 and non-small cell lung carcinoma: Furthermore, bortezomib can synergistically reduce the expression of mutated p53 proteins in NSCLC when used with other treatments that are similar to PCC, such as venetoclax and navitoclax, as mediators of pro-survival proteins [43].